佛慈制药：2026年公司将持续推进大单品和大市场开发战略

Core Insights - The company plans to continue its strategy of developing major products and markets through 2026, focusing on core products to drive overall sales growth [2] Product Strategy - The company aims to consolidate and enhance the market share of its traditional concentrated pill products, particularly the Liuwei Dihuang Wan series [2] - There will be an increased focus on the sales of exclusive products such as the Shenrong Guben Huan Shao Wan and the Compound Huangqi Jianpi Oral Liquid, as well as other high-demand products like Erchen Wan, Angong Niuhuang Wan, Bazhen Wan, and Anshen Buxin Wan [2] Market Development - The company is concentrating on its base markets in Shaanxi and Gansu while strengthening its national market layout and channel development [2] - There is a specific emphasis on expanding into the South China market and international markets to gradually enhance market competitiveness and increase market share and product sales [2]